Our One JBCPL family has completed its 44th year. Being one of thefastest-growing pharmaceutical companies in India we have good reason to be pleased. Evenso we are not content. We are already looking ahead and accelerating towards our 50thyear in 2025. In this journey we will focus on strengthening our core capabilities andalso build an organisation that is agile and resilient to uncertain times.
Before discussing the future I would like to express my heartfelt thanks to all thosewho have been battling Covid-19 for over a year by working tirelessly and selflessly tomitigate the impact of this pandemic. Covid-19 has shifted the method and pace ofhealthcare delivery. It has sensitised us to the need for greater speed integration andquality of response across manufacturing supply chain sales marketing quality controland assurance (QA-QC) and R&D.
At JBCPL we are applying our learnings to establish plans for the future.
Business transformation initiatives:
Our major focus is to strengthen our core therapy segments i.e. hypertensiongastroenterology nephrology cardiology dentistry and paediatrics. In FY 21 werealigned our structure and portfolio to ensure sustainable growth and put a strong focuson the lifecycle management of our flagship brands.
The next priority is to scale up R&D and business development initiativestowards building a progressive portfolio for our US ROW Russia SA API and CMObusinesses.
We will focus on consolidating our business areas through a deeper presence inexisting geographies this will be aided by new launches over the next 2-3 years.
We are investing in beyond the pill initiatives tech-enabled solutionsand a phygital approach to innovatively meet the diverse needs of internalstakeholders employees associates and HCPs (Healthcare Professionals).
Moving into newer therapeutic categories:
In the past few months we have ventured deeper into therapeutic segments where wealready have equity as well as expanded into adjacent therapies where we believe we canenhance the quality of care for patients.
Nephrology - We have introduced a range of products to support the treatment ofkidney disease. These will leverage our formidable equity with nephrologists and furtherexpand our market share in this category.
Respiratory - Respiratory diseases are the most common disease conditions whichimpact every socio-economic and age group in society. We have introduced a comprehensiveportfolio for treating respiratory allergy virology and ILD.
Diabetes - We entered the fastest-growing category of the Indian pharmaceuticalsmarket with the launch of DPPIV and SGLT2 inhibitor molecules. These leverage our strengthin the cardio-metabolic segment.
Nicotine Replacement Therapy (NRT) - We extended our lozenges expertise to NicotineReplacement Therapy in India with introduction of our NOSMOK lozenges.
Adding and upgrading resources & processes:
We have hired leaders for key positions in the domains of R&D QA-QC IR LegalCompany Secretary and Finance to strengthen our expertise and operate with the higheststandards of governance and control. We now have a good mix of talent and able leadershipin place to meet our aspirations for 2025.
We are exploring possible M&A opportunities which can complement our strengthsand accelerate our performance in key segments.
Structured programs in the organisation aimed at improving our supply service andcost-efficiency. This will enhance our profitability and business growth.
All these initiatives are being carried out with full commitment and passion towardsone singular purpose which is to do more good for more people. However large andsuccessful our business becomes we will always retain the spirit of JBCPL.
We believe that we are big enough to create a positive impact for patients andhealthcare providers yet small enough to still care.